ClinicalTrials.gg
RecruitingNCT06630728LOWFLCUpdated Oct 29, 2026

Addiction Potential of Very Low Nicotine Filtered Little Cigars

A Phase 4 interventional study of Reduced Nicotine Content Cigars and Normal nicotine content cigar in Smoking (Tobacco) Addiction, sponsored by Ohio State University Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 21 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Ohio State University Comprehensive Cancer Center · Phase 4, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Oct 29, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 899 studies in Smoking with a site in United States — 90 open to participants now, 110 under way, 4 of them phase 3. Smoking · United States.

Planned enrollment
548th of 785
50 · median 109
Started
2025
with 23 others
Phase 4
67 of 899
5 open now
Primary completion
2028-12
later than 90 of 109 live
Registered
835th of 899
by date

Among the 899 studies in Smoking with a site in United States, this one is the 548th largest by planned enrollment of the 785 interventional ones that give a count, is one of 24 that started in 2025, is one of 67 in phase 4, reaches primary completion later than 90 of the 109 other live ones, and was the 835th registered.

Smoking

1,516 studies on the registry are indexed under Smoking; 196 are open to participants now.

Browse Smoking studies →

Open to participants now

90 of the 899 studies in Smoking with a site in United States are open now. Recruiting first, the newest first:

85 more — sign in →

All 90 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Smoking studies recruiting now, 76 (52%) set no upper age limit and 51 (35%) stop at 75 or younger; 3 take children under 18; 69 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 899 studies in Smoking with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn how reducing the nicotine content in filtered little cigars can affect the the use of these cigars and lung health in current adult filtered little cigar users. The main question[s] it aims to answer are:

Are puffing behaviors, appeal/satisfaction, craving suppression, pharmacokinetic effects, and demand similar between the regular cigars smoked by participants, normal nicotine study cigars and very low nicotine study cigars? Are health effects and toxicant exposure similar between the regular cigars smoked by participants, normal nicotine study cigars and very low nicotine study cigars?

Participants will attend three study visits at OSU. Each visit would last up to 4 hours. During visits, they will

  • fill several surveys
  • provide blood samples
  • perform breathing tests
  • complete smoking sessions using either their own cigars or the study cigars.
03

Conditions studied

  • Smoking (Tobacco) Addiction
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Smokers: 1) self-reported regular current filtered little cigars, cigarillos, little cigars, or small cigars use for the past 3 months; regular use will be defined as >=8 cigars smoked per month based on data showing median cigarillo use is 7.5 times per month and median FLC use is 14 times per month 59. We will attempt to bring in heavier users if feasible during recruitment; or 2) Cigarette smokers (>=8d/month for at least 3 months) with either (i) co-use of filtered little cigars, cigarillos, little cigars, or small cigars (at least once in their lifetime) or (ii) answering "yes" to the question "If all cigarettes were taken off the market, would you consider switching to filtered little cigars?"
  • willing to abstain from all tobacco and nicotine for at least 12 hours prior to lab sessions
  • Willing to bring their own, preferred brand little cigars/ small cigars/ cigarillos/ filtered little cigars to smoke in the lab on the first study visit
  • capable of and willing to provide written
  • read and speak in English.

Exclusion criteria

Exclusion Criteria:

  • Self-reported significant current lung disease (e.g. asthma, , cystic fibrosis, pulmonary fibrosis); exercise-induced asthma, seasonal allergies for which a patient takes inhalers are allowed
  • History of diagnosis or treatment for lung cancer
  • Self-reported serious or uncontrolled kidney disease, liver disease, metabolic disease (thyroid, diabetes)
  • History of cardiac event or distress within the past 3 months
  • Unstable or significant psychiatric conditions (past and stable conditions will be allowed)
  • Substance use disorders besides nicotine addiction
  • Regular use of other tobacco products besides cigarettes such as snuff, chewing tobacco, snus, e-cigarettes >10d per month
  • Exclusive large or premium cigar users
  • Use of blunts every time or most of the time
  • Regular use of cannabis >10d per month
  • Planning to quit in next 30 days or currently trying to quit or quit attempt in past 30 days
  • Pregnant, delivery in past 12 weeks, breastfeeding, or planning to get pregnant
  • Inability to perform tests or follow instructions during testing
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Smoking session

    All participants will undergo three smoking sessions: one using their own usual brand cigar, one with a normal nicotine study cigar, and one with a reduced nicotine study cigar

    Drug: Reduced Nicotine Content Cigars · Drug: Normal nicotine content cigar · Drug: Usual brand cigar

Interventions

  • DrugReduced Nicotine Content Cigars

    Participants will smoke a very low nicotine content filtered little cigar containing 0.50mg nicotine per gram of tobacco

    Also known as: VLNFLC

  • DrugNormal nicotine content cigar

    Participants will smoke a normal nicotine content filtered little cigar containing 5.17mg nicotine per gram of tobacco

    Also known as: FLC

  • DrugUsual brand cigar

    Participants will smoke their usual brand filtered little cigar

    Also known as: UB

06

What researchers measure

Primary outcomes

  1. Drug self-administration- Puff topography- total puff volume

    Derived from puff topography, total puff volume indicates the total amount of smoke inhaled during the smoking session. Units: mL

    Time frame: During session 65 minute puffing session

  2. Forced expiratory volume in 1 second

    Spirometry will be completed before and after a 65 min smoking session

    Time frame: Change from 0 to 65 minutes

  3. Nicotine

    Plasma sample will be analyzed for nicotine to assess pharmacokinetics from before to 5 minutes after the smoking session

    Time frame: Change from 0 to 5 minutes

  4. Nicotine

    Plasma sample will be analyzed for nicotine to assess pharmacokinetics from before to 65 minutes after the smoking session

    Time frame: Change from 0 to 65 minutes

  5. Carbon monoxide boost

    Exhaled carbon monoxide (CO) will be measured for assessing CO boost as a measure of toxicity before and 5 minutes after the smoking session

    Time frame: Change from 0 to 5 minutes

  6. Carbon monoxide boost

    Exhaled carbon monoxide (CO) will be measured for assessing CO boost as a measure of toxicity before and after the smoking session

    Time frame: Change from 0 to 65 minutes

Secondary outcomes

  1. Functional residual capacity

    Functional residual capacity will be measured with plethysmography to assess dynamic hyperinflation after the smoking session

    Time frame: Change from 0 to 65 minutes

  2. Airway resistance (R5)

    Impulse oscillometry will be used to measure total airway resistance before and after the smoking session

    Time frame: Change from 0 to 65 minutes

  3. Airway resistance (R5-R20)

    Impulse oscillometry will be used to measure small airway resistance before and after the smoking session

    Time frame: Change from 0 to 65 minutes

  4. Modified Cigarette Evaluation Scale

    The 12-item modified Cigarette Evaluation Scale will provide subjective effects of smoking cigars on a 0-6-point Likert scale from "not at all" to "extremely". There are five subscales including smoking satisfaction, psychological reward, enjoyment of respiratory symptoms, craving reduction, and aversion

    Time frame: 65 minutes

  5. Questionnaire on Smoking Urges (Tiffany Drobes)

    Smoking urges/craving will be measured using the Tiffany-Drobes Questionnaire of Smoking Urges: Brief Form. This is a 10-item measure where participants rate smoking-related items (All I want right now is a cigarette) on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree). Similar to previous studies, we will collapse the items into two previously identified factors (Factor 1: strong desire and intention to smoke; Factor 2: anticipation of relief from withdrawal symptoms). Scores are calculated by summing the items and range from 5 to 35 with higher scores indicating greater craving to smoke

    Time frame: Change from 0 to 5 minutes

  6. Questionnaire on Smoking Urges (Tiffany Drobes)

    Smoking urges/craving will be measured using the Tiffany-Drobes Questionnaire of Smoking Urges: Brief Form. This is a 10-item measure where participants rate smoking-related items (All I want right now is a cigarette) on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree). Similar to previous studies, we will collapse the items into two previously identified factors (Factor 1: strong desire and intention to smoke; Factor 2: anticipation of relief from withdrawal symptoms). Scores are calculated by summing the items and range from 5 to 35 with higher scores indicating greater craving to smoke

    Time frame: Change from 0 to 65 minutes

  7. Minnesota Nicotine Withdrawal Scale

    Nicotine withdrawal will be assessed using the empirically validated 15-item version of the Minnesota Nicotine Withdrawal Scale (MNWS). Items were rated on a 5-point scale from 0 (none) to 4 (severe). This measure assesses smoking craving, anger/irritability, anxiety, depressed mood, restlessness/difficulty concentrating, increased appetite, sleep problems, and somatic symptoms (nausea, constipation, sore throat, dizziness, coughing). MNWS is the sum of 7 items with scores ranging from 0 to 28 and MNWS Craving is a single item with scores ranging from 0 to 4, higher scores indicate a greater craving.

    Time frame: Change from 0 to 5 minutes

  8. Minnesota Nicotine Withdrawal Scale

    Nicotine withdrawal will be assessed using the empirically validated 15-item version of the Minnesota Nicotine Withdrawal Scale (MNWS). Items were rated on a 5-point scale from 0 (none) to 4 (severe). This measure assesses smoking craving, anger/irritability, anxiety, depressed mood, restlessness/difficulty concentrating, increased appetite, sleep problems, and somatic symptoms (nausea, constipation, sore throat, dizziness, coughing). MNWS is the sum of 7 items with scores ranging from 0 to 28 and MNWS Craving is a single item with scores ranging from 0 to 4, higher scores indicate a greater craving.

    Time frame: Change from 0 to 65 minutes

  9. Hypothetical purchase task

    Hypothetical purchase task offers a measure of relative reinforcing efficacy. It will be completed after each smoking session. It assesses how many cigars a participant would smoke in a 24-hour period at various hypothetical price conditions and has been used to characterize addiction potential for reduced nicotine content cigars vs. normal nicotine content cigars vs. usual brand cigars. Data from the task leads to five demand indices (intensity or consumption with no cost constraint, price point at which consumption becomes sensitive to price, breakpoint is the price where FLCs are no longer purchased because of high price, largest cost that a participant is willing to incur to purchase FLCs, and elasticity as a measure of the overall sensitivity of FLC consumption to escalating price that measures how behaviors would change under the constraint of increased price).

    Time frame: 65 minutes

  10. Cross-price task

    The Cross-Price Task will estimate the substitutability of the study cigars for the usual brand cigars. It will be completed after each study product smoking session. Participants will be asked how many study products and usual products they would consume when the price of the study product is fixed and the usual product prices escalate. To determine the extent to which each alternative product serves as a substitute for the study product, cross-price elasticities (CPE) will be calculated as the slope of the regression line (B1) fit to the log-transformed mean purchasing of each study product when offered at fixed prices (C) versus log-transformed usual product price (P): logC = B0 + B1logP. CPE for each study product compared to UB product \> 0.2 indicates substitution, CPE \< -0.2 indicates complementarity, and CPE between -0.2 and 0.2 indicates independence of the two products

    Time frame: 65 minutes

07

Study locations

1 of 1 sites recruiting
  • The Ohio State University
    Columbus, Ohio 43210, United States
    Recruiting
    • Dharini M Bhammar, PhD, MBBS · Contactdharini.bhammar@osumc.edu · 614-366-9467
    • Dharini M Bhammar, PhD, MBBS · Principal investigator
    • Theodore Wagener, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2028, 46 months after the start.

Of 29 non-industry phase 4 interventional studies under Smoking, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 46 months is above that.

Counting every sponsor, half of 29 studies reached it within 35 months; a quarter within 18 and three quarters within 71.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Dec 2027 → Dec 2028 and completion Jan 2028 → Jan 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2024
First posted
Oct 8, 2024
StartActual
Feb 13, 2025
Primary completionEst.
Dec 2028was Dec 2027
CompletionEst.
Jan 2029was Jan 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2027→Dec 2028
Oct 29, 2026
Study completion
Jan 2028→Jan 2029
Oct 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • The Ohio State University · Columbus, United StatesContact removed L•••@osumc.edu · •••7843
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Primary completion Dec 2027→Dec 2028
    Study completion Jan 2028→Jan 2029
    Site contacts Changed at 1 site. See the sites
    Show the site
    • The Ohio State University · Columbus, United StatesContact removed L•••@osumc.edu · •••7843
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06630728
Responsible party
Dharini Bhammar (Assistant Professor, Ohio State University Comprehensive Cancer Center) — Principal investigator
First posted
Oct 8, 2024
Start date
Feb 13, 2025
Primary completion
Dec 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Oct 29, 2026

Study contacts

Dharini M Bhammar, PhD, MBBS
Contact
dharini.bhammar@osumc.edu
614-366-9467
The Ohio State University Comprehensive Cancer Center
Contact
OSUCCCClinicaltrials@osumc.edu
800-293-5066
Dharini M Bhammar, PhD, MBBS
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion